Actively Recruiting
Obe-cel in Refractory Progressive Forms of Multiple Sclerosis
Led by Autolus Limited · Updated on 2026-03-23
18
Participants Needed
7
Research Sites
210 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main purpose of this study is to evaluate if obe-cel is safe or causes any side effects in adults with refractory progressive MS. The study also plans to assess if obe-cel can show early signs of efficacy in MS. The trial includes only 1 group of participants (single-arm). The study population comprises participants with progressive forms of MS, not responsive to highly effective therapies. Upon confirmation of study eligibility, participants will receive chemotherapy (used here for lymphodepletion) over 1 to 3 days in preparation for receiving a single obe-cel infusion. Participants will be checked closely in the 28 days following obe-cel treatment. After this, participants will be monitored to evaluate safety and efficacy up to 24 months.
CONDITIONS
Official Title
Obe-cel in Refractory Progressive Forms of Multiple Sclerosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willing and able to give written informed consent for participation in the study.
- Ability and willingness to follow the study schedule and requirements.
- Age between 18 and 60 years inclusive at informed consent.
- Female participants must not be pregnant or breastfeeding.
- Current diagnosis of progressive multiple sclerosis.
- Previously treated with at least two disease-modifying therapies.
You will not qualify if you...
- Use of any medications prohibited by the study protocol.
- Presence of highly active multiple sclerosis.
- Diagnosis of another autoimmune central nervous system condition.
- Active or uncontrolled fungal, bacterial, or viral infections.
- History of cancer unless disease-free for at least 24 months.
- History of heart, lung, kidney, liver transplant, or hematopoietic stem cell transplant.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Stanford University
Redwood City, California, United States, 94063
Not Yet Recruiting
2
Hospital Universitario Vall d'Hebron - PPDS
Barcelona, Spain
Active, Not Recruiting
3
Hospital Universitari i Politecnic La Fe de Valencia
Valencia, Spain
Actively Recruiting
4
Addenbrooke's Hospital
Cambridge, United Kingdom
Actively Recruiting
5
Western General Hospital Edinburgh - PPDSE Edinburgh
Edinburgh, United Kingdom
Actively Recruiting
6
The National Hospital for Neurology & Neurosurgery
London, United Kingdom
Actively Recruiting
7
Royal Hallamshire Hospital
Sheffield, United Kingdom
Actively Recruiting
Research Team
A
Autolus Ltd
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here